An unstoppable force is quietly reshaping America.
A force you can feel weighing on you… but can’t quite explain.
I know you feel it because I feel it too… and so does every American I’ve spoken with: rich or poor, left-wing or right-wing, young or old. It’s a dark cloud hanging over the nation.
Ever since I first felt this strange phenomenon, I’ve devoted nearly every waking hour to understanding it.
What my investigation has unearthed is something I have never seen covered by any publication or media outlet… and that deeply concerns me.
Because after years of pulling on this thread, I’ve come to realize it is not random. It’s not just in our heads. It’s a very real, immensely powerful force.
One that often lies dormant for centuries… but when it’s triggered, it always unleashes a seismic chain reaction that changes everything.
For the good… and for the bad. Now, maybe you suspect this has something to do with our toxic politics, ever-widening wealth gap, or the culture war consuming the country…
But those are just symptoms.
Surface-level manifestations of a far deeper, far more dangerous force… one that’s secretly been building for years.
A force two Nobel Prize winners warn will divide America, permanently.
And that I believe is going to happen far faster than anyone imagines, with one of the world’s leading evolutionary biologists warning:
“The scale and speed [of this displacement] is going
to result in [an] unprecedented catastrophe.”
That’s not a prediction. It’s happening right now.
And mark my words: you and I have never seen anything like this before: the dot-com collapse, global financial crisis, COVID-19 pandemic… nothing we’ve seen in our lifetime holds a candle to what’s coming next.
My research reveals that events of this magnitude have only happened four times across the vast expanse of human history… and each one defined an entirely new epoch.
They’ve toppled and raised empires… started and ended wars… usurped kings... reshaped political systems… and lifted millions from poverty while condemning millions more to the poor house.
As historian Neil Postman explains it, these moments are “both a burden and a blessing – not either-or but this and that.”
Now, we’re living through another one.
And as you’ll see, I – and many of the world’s leading experts – believe this could be The Final Displacement.
A turning point that the former CEO of Google says is:
“The most important thing that’s going to happen in about 500 years – maybe 1,000 years of human society – and it’s happening in our lifetime.”
As it unfolds, it threatens to upend every aspect of our daily lives from how we work, how we provide for loved ones to how we save and invest for the future.
Yet nobody is fully warning you of what’s coming.
Until now.
In my new documentary, I lay everything out for you.
And it’s critical that you pay close attention because as you’ll see, I believe we are about to be plunged into a period of dramatic, almost unimaginable change.
Politicians, companies, and economies will rise and fall, the most sacred of our social contracts will be rewritten, and our ways of life that’ve stood for generations will be swept away in the blink of an eye.
And, of course, throughout it all…
Vast fortunes will be made and lost.
I’m talking about a generational transfer of wealth… the type that can either enrich you or impoverish you, based on the decisions you make in the days and weeks ahead.
Because history shows us that while these societal shifts always lead to catastrophic losses for those who refuse to prepare…
… they also unleash unprecedented wealth building potential for those who understand, and harness, the forces at work.
I want to make sure you’re on the winning side.
Watch my new documentary, The Final Displacement, now.
➡ Click here to stream it at no cost.
Good investing,
Porter Stansberry
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
Written by Chris Markoch. Published 11/5/2025.
Key Points
- Hims & Hers posted 49% YOY revenue growth but flat earnings and lower margins in Q3.
- Discussions with Novo Nordisk could enable Hims to offer Wegovy on its platform, thereby expanding access to GLP-1.
- High short interest and valuation keep HIMS stock range-bound despite strong top-line growth.
Hims & Hers Health Inc. (NYSE: HIMS) stock is holding a slight gain the day after the company delivered a mixed third-quarter earnings report. Investor caution centers on the company's valuation, which makes it an outlier among healthcare stocks.
The company reported quarterly revenue of $598.98 million, a 49.2% year-over-year (YOY) increase and about $20 million above analysts' estimates. On the bottom line, earnings per share (EPS) of $0.09 matched estimates but were down 71% YOY. That weakness showed up in gross margin, which came in at 74%, down 5 percentage points year over year.
Gold revaluation imminent? (Ad)
You're almost out of time to place this "Debasement Trade"
Wall Street has been making headlines for piling into a strange new money move they're calling the "Debasement Trade"... And it could affect you and your money in a MAJOR way. According to Dr. David Eifrig, a former Goldman Sachs executive who has traded profitably through just about every stock market situation you can imagine, including Black Monday… the clock is ticking for you to get your money in the right place. He's just released a free, brand-new briefing that explains exactly what's happening and the No. 1 financial step to take immediately.
On the subscriber front, Hims & Hers said total subscribers rose by roughly 30,000 during the quarter — about a 20% YOY increase — which the company attributes to its focus on personalized solutions.
Higher subscriber counts should support topline growth and, over time, earnings expansion. Analysts are forecasting the company's earnings to grow roughly 79.3% over the next 12 months.
A New Deal With Novo Nordisk Could Shrink the Company’s Risk Premium
One highlight of the report was confirmation that Hims & Hers and Novo Nordisk are in active discussions. If those talks succeed, Hims would be able to offer Wegovy on its platform in both injectable and oral forms.
Importantly, the company said there is no definitive agreement and acknowledged the possibility that talks may not result in a deal — a factor likely keeping a lid on HIMS shares.
Still, the potential partnership helps explain investor enthusiasm. HIMS has climbed roughly 88% year to date in 2025, but timing matters: investors who bought at the February peak are still sitting on losses of about 34%.
Part of the stock's volatility stemmed from the company's push into the GLP‑1 market. Hims & Hers announced plans to offer an affordable GLP‑1 alternative to brand names such as Ozempic and Wegovy amid surging demand.
Those ambitions ran into regulatory scrutiny after the company's compounded GLP‑1 product — not FDA‑approved and potentially variable in potency and formulation — drew concerns. Hims & Hers has said it is taking a measured approach to the category.
Is Short Interest a Risk or an Opportunity?
Short interest in HIMS is elevated at roughly 35% of the float, though that level is down about 3 percentage points over the past month, signaling persistent bearish sentiment among traders.
The stock carries a forward price-to-earnings (P/E) ratio near 162x, putting it on par with some expensive tech names. P/E is a useful metric, but investors should weigh it alongside growth prospects, regulatory risk, and market dynamics.
HIMS Stock Is Range Bound, But the Downside Risk Looks Contained
The post‑earnings move reinforces that HIMS remains range‑bound. Analyst sentiment is mixed and short interest is high. While the quarterly results were constructive, it's unclear whether they will be enough to lift the stock materially.
Technically, downside appears somewhat limited. As of this writing, the stock is trading at $44.53, below its 50‑day simple moving average (SMA). Daily volume is steady, indicating sustained — but not aggressive — market participation.
The relative strength index (RSI) sits around 42, suggesting limited buying conviction and risk of further weakness. Negative MACD lines point to negative momentum, though there are signs they may be reversing.
The chart calls for caution, but if HIMS holds above recent support near $41 a share, downside should be contained.
This email communication is a paid advertisement from Porter & Company, a third-party advertiser of The Early Bird and MarketBeat.
If you need assistance with your newsletter, please feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2025 MarketBeat Media, LLC.
345 N Reid Pl. #620, Sioux Falls, SD 57103-7078. United States of America..